← All trials
NCT05205746
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 23, 2021
- Primary completion
- Aug 9, 2022
- Completion date
- Jan 23, 2023
- First posted
- Jan 25, 2022
- Last posted
- Sep 28, 2022
- Enrollment
- 158
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Laboratorio Avi-Mex, S.A. de C.V.Lead sponsor
- Instituto Nacional de Enfermedades RespiratoriasCollaborator
- Government of MexicoCollaborator
- Unidad Médico Familiar No. 20 Instituto Mexicano del Seguro SocialOverall official - principal investigator
- Unidad Médico Familiar No. 20 Instituto Mexicano del Seguro SocialOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.